Chemists have succeeded for the first time in manufacturing pharmaceutical cholesterol from plant-based materials. In future it will be possible to supply large quantities of the molecule for the production of modern mRNA-based vaccines.
Varying immune response to vaccinations could be countered with microbiota-targeted interventions helping infants, older people and others to take full advantage of the benefits of effective vaccines, Australian experts say.
A comprehensive review in Nature Reviews Immunology concludes that evidence is mounting in clinical trials and other studies that the composition and function of individuals gut microbiota are crucial factors in affecting immune responses to vaccinations
E-Mail
What The Study Did: Study results suggest that reinfections are rare events and that patients who have recovered from COVID-19 have a lower risk of reinfection. However, the observation ended before SARS-CoV-2 variants began to spread, and it is unknown how well natural immunity to the wild-type virus will protect against variants. .
Authors: Nicola Mumoli, M.D., of the Ospedale Fornaroli in Magenta, Italy, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https:/
E-Mail
LA JOLLA, CA Even before the COVID-19 pandemic, most people in the United States already had been sick with a coronavirus, albeit a far less dangerous one. That s because at least four coronaviruses in the same general family as SARS-CoV-2 cause the benign yet annoying illness known as the common cold.
In a new study that appears in
Nature Communications, scientists from Scripps Research investigated how the immune system s previous exposure to cold-causing coronaviruses impact immune response to COVID-19. In doing so, they discovered one cross-reactive coronavirus antibody that s triggered during a COVID-19 infection.
The findings will help in the pursuit of a vaccine or antibody treatment that works against most or all coronaviruses, says senior author Raiees Andrabi, PhD, an investigator in the Department of Immunology and Microbiology.
In a new study, scientists at HKUST have revealed that most T cell epitopes known to be targeted upon natural infection are seemingly unaffected by current SARS-CoV-2 variants.